SC
Sami Corwin
Compare →Biotech Equity Research Analyst at William Blair
Sami Corwin, Ph.D., is a Biotech Equity Research Analyst at William Blair, focusing on cell therapy, gene therapy, and rare diseases. With nearly 15 years of experience, she has been with William Blair since November 2018, previously serving as an Equity Research Associate in the biotechnology sector. Sami holds a Ph.D. in neuroscience from the University of Illinois–Chicago and a B.S. in biology from UC Irvine.
No chart yet. A chart needs 8 resolved predictions, and Sami has 5. The predictions themselves are below.
SORT
STILL OPEN
?
uniQure will reach a price of $73 within 12 months of Sep 2, 2026.
Due Sep 2, 2027September 2, 2026Price targetEquitiesPending
—
SCORE
?
Obsidian Therapeutics will reach a price of $43 within 12 months of Sep 9, 2026.
Due Sep 9, 2027September 9, 2026Price targetEquitiesPending
—
SCORE
?
Corwin views the goal of four commercial therapies by 2030 as realistic.
Due Dec 31, 2030August 3, 2026PharmaceuticalsTherapiesPending
—
SCORE
?
Corwin believes Krystal’s strategy to have four commercial therapies in rare diseases by 2030 is realistic, given the expected progression of two additional programs into registrational trials by 2027.
Due Dec 31, 2030August 3, 2026PharmaceuticalsRare DiseasesPending
—
SCORE
?
Sign in to read this call.
September 3, 2026PharmaceuticalsPending
—
SCORE
?
Management’s progress on the rolling BLA for miv-cel in stiff person syndrome reinforces the potential to secure the first approved CAR T-cell therapy in an autoimmune disease.
June 3, 2026BiotechRegulatoryPending
—
SCORE
RESOLVED · NEWEST FIRST
◇
Sami Corwin initiates coverage on Obsidian Therapeutics with an outperform rating.
own side · their own organization · resolved, earns no score
September 9, 2026PharmaceuticalsNot settleable
—
SCORE
◇
Corwin projects revenue growth acceleration by 2026, driven by international launches and strong patient feedback.
August 3, 2026PharmaceuticalsRevenue GrowthToo vague to check
—
SCORE
✗
Sami Corwin initiates coverage on Ultragenyx Pharmaceutical with a price target of $65.
May 28, 2025call #5PharmaceuticalsWrong
0
SCORE
✓
Sarepta’s ongoing pipeline developments are anticipated to provide further positive momentum for the stock.
March 18, 2025call #4pipelinegrowthCorrect
52
SCORE
✓
The company’s first in vivo program will enter clinical trials in the first half of 2024.
March 26, 2024call #3biotechnologyclinical trialsCorrect
97
SCORE
◇
Sign in to read this call.
March 19, 2024biotechnologypatient startsNo verdict
—
SCORE
✓
Sign in to read this call.
March 19, 2024call #2biotechnologyrevenueCorrect
88
SCORE
✓
Sign in to read this call.
May 30, 2023call #1BiotechnologyCorrect
82
SCORE
◇
Sign in to read this call.
September 29, 2022FinanceStockNot settleable
—
SCORE
Still open · 6
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
uniQure will reach a price of $73 within 12 months of Sep 2, 2026.
Due Sep 2, 2027Said September 2, 2026Price targetEquities
?No market prices this claim
Obsidian Therapeutics will reach a price of $43 within 12 months of Sep 9, 2026.
Due Sep 9, 2027Said September 9, 2026Price targetEquities
?No market prices this claim
Corwin views the goal of four commercial therapies by 2030 as realistic.
Due Dec 31, 2030Said August 3, 2026PharmaceuticalsTherapies
?No market prices this claim
Corwin believes Krystal’s strategy to have four commercial therapies in rare diseases by 2030 is realistic, given the expected progression of two additional programs into registrational trials by 2027.
Due Dec 31, 2030Said August 3, 2026PharmaceuticalsRare Diseases
?No market prices this claim
Sign in to read this call.
Said September 3, 2026Pharmaceuticals
?No market prices this claim
Management’s progress on the rolling BLA for miv-cel in stiff person syndrome reinforces the potential to secure the first approved CAR T-cell therapy in an autoimmune disease.
Said June 3, 2026BiotechRegulatory